KPV
Also known as: Lys-Pro-Val, Lysine-Proline-Valine, α-MSH (11–13), alpha-MSH C-terminal tripeptide
4 notable studies · 5 references
TLDR
KPV is a three-amino-acid peptide studied for its effects on inflammatory signaling, particularly in the intestine, with encouraging laboratory and animal findings but no established clinical benefit in humans.
Research Supports
- Reduced inflammatory markers in mouse models of colitis
- Decreased NF-κB and MAP kinase signaling activity in laboratory experiments
- Cellular entry via the PepT1 peptide transporter in intestinal and immune cells
- Anti-inflammatory activity reported across multiple nanoparticle-delivery studies
Observations Reported in Research
- Improved body-weight recovery in colitis-model mice (Kannengiesser et al., 2008)
- Reduced pro-inflammatory cytokine production in human-derived intestinal cell lines (Dalmasso et al., 2008)
- Some anti-inflammatory activity observed independently of the MC1R receptor
- Reduced inflammatory tissue changes when delivered via a polysaccharide hydrogel nanoparticle system (Laroui et al., 2010)
These are brief summaries of what the referenced research examined or reported — not conclusions about safety or effectiveness, and not medical advice. See Notable Studies and Sources & References below for the full context and citations.
At a Glance
Classification: Naturally occurring tripeptide; C-terminal fragment of alpha-melanocyte-stimulating hormone (α-MSH); melanocortin-derived peptide investigated for anti-inflammatory activity
KPV consists of three amino acids with a surprisingly interesting research story. KPV is a small peptide made up of lysine, proline, and valine. It's a fragment of a larger hormone called alpha-melanocyte-stimulating hormone (α-MSH), which is involved in several biological processes, including inflammatory signaling. What makes KPV interesting is that researchers have observed anti-inflammatory effects from this tiny fragment in laboratory experiments and animal studies. Much of the published research focuses on inflammation in the digestive tract, where KPV has been investigated for its effects on intestinal cells, inflammatory signaling pathways, and experimental colitis.
What Is KPV?
KPV is a peptide consisting of just three amino acids: lysine (K), proline (P), and valine (V). Its name comes directly from the one-letter abbreviations for those amino acids. It is also the final three-amino-acid segment of alpha-melanocyte-stimulating hormone, commonly shortened to α-MSH. Scientists have studied α-MSH for its involvement in pigmentation and the regulation of inflammatory responses. KPV attracted attention because researchers found that this much smaller fragment could retain certain anti-inflammatory effects in experimental models. Think of it as researchers discovering that a small piece of a larger biological molecule can still influence some of the same cellular processes. One particularly interesting area of KPV research involves the intestine. In laboratory experiments, KPV has been shown to enter certain cells through a peptide transporter called PepT1 and influence pathways involved in inflammatory signaling. Researchers have also studied KPV in mice with experimentally induced intestinal inflammation, observing reductions in several measures of inflammatory activity. These findings make KPV a subject of ongoing scientific interest, especially in research involving intestinal inflammation and peptide transport.
What Are Researchers Studying?
Intestinal inflammation
Researchers are studying KPV's effects on inflammation in the digestive tract. In mouse models of colitis, KPV has been associated with reductions in certain inflammatory markers and improvements in colon tissue findings. These preclinical results help explain the interest in KPV, but they do not establish that it can treat inflammatory bowel disease in humans.
Inflammatory signaling
Laboratory studies suggest that KPV can influence cellular pathways involved in inflammation, including NF-κB and MAP kinase signaling. Researchers are investigating how these effects alter the production of inflammatory signaling molecules and whether the same mechanisms operate in more complex biological systems.
Cellular uptake and peptide transport
Researchers have investigated how KPV enters cells through PepT1, a transporter that carries certain small peptides across cell membranes. Understanding this process may help explain how KPV interacts with intestinal and immune cells and why its effects vary across experimental conditions.
Targeted intestinal delivery
Scientists have explored specialized delivery systems, including nanoparticles, designed to transport KPV to inflamed intestinal tissue. These experiments examine how delivery methods influence the peptide's distribution and observed effects in preclinical models. Results from these engineered formulations cannot automatically be applied to other forms of KPV.
How Does It Work?
KPV appears to influence several processes involved in how cells respond to inflammatory signals. One of the most interesting findings involves a transporter called PepT1. PepT1 is a protein that helps move certain small peptides into cells. It is normally expressed in the small intestine and can also be expressed in the colon during intestinal inflammation. In a 2008 study, researchers found that KPV could enter intestinal epithelial cells and immune cells through PepT1. Once inside the cells, KPV was associated with reduced activity in inflammatory signaling pathways, including NF-κB and MAP kinase pathways. These pathways help regulate how cells respond to inflammatory stimuli and influence the production of signaling molecules called cytokines. In the experiments, KPV reduced the production of certain pro-inflammatory cytokines. Other research suggests that at least some of KPV's anti-inflammatory activity may occur independently of the melanocortin-1 receptor (MC1R), a receptor involved in some biological effects of the larger α-MSH hormone. Together, these findings suggest that KPV may influence inflammatory responses through more than one biological mechanism.
What Does the Research Show?
Human research
Human clinical evidence: Not established. The KPV studies discussed in this profile do not demonstrate that KPV is safe or effective as a treatment in humans. Some laboratory experiments have used human-derived intestinal epithelial cells and immune-cell lines. Although these cells originate from humans, experiments performed on isolated cells are classified as in-vitro research—not human clinical trials. The animal studies discussed below also cannot establish clinical benefits in people; questions about human effectiveness, safety, long-term effects, and appropriate clinical delivery remain unanswered.
Animal research
Evidence type: Preclinical animal studies KPV has been investigated in several mouse models of intestinal inflammation. In a 2008 study published in Inflammatory Bowel Diseases, researchers examined KPV in two different mouse models of colitis. The KPV-treated mice showed improvements in measures such as recovery of body weight, inflammatory-cell infiltration, and inflammatory changes observed in colon tissue. Another study, published in Gastroenterology in 2008, examined KPV in mouse models of colitis induced by two different experimental agents. Researchers reported reductions in inflammatory markers and several measures of intestinal inflammation in the KPV-treated groups. Subsequent research explored specialized nanoparticle delivery systems designed to carry KPV to inflamed areas of the colon. These studies reported improvements in certain inflammatory measures in mouse models. Taken together, the animal findings provide a rationale for further investigation.
In-vitro research
Evidence type: Laboratory experiments involving isolated cells Laboratory studies have helped researchers investigate how KPV interacts with cells and inflammatory signaling pathways. In a 2008 study, researchers used human-derived intestinal epithelial cell lines and a human T-cell line to examine KPV's effects under experimentally induced inflammatory conditions. They observed that KPV could be transported into cells through PepT1. The experiments also showed reduced activation of NF-κB and MAP kinase signaling pathways and reduced production of certain pro-inflammatory cytokines. Other laboratory research has investigated specialized delivery systems intended to transport KPV to intestinal cells. These experiments help researchers understand possible mechanisms and investigate how different formulations behave.
Notable Studies
PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation
in-vitroWhat researchers investigated: Whether the PepT1 transporter helps KPV enter intestinal and immune cells, and whether KPV influences inflammatory responses in experimental mouse models of colitis. What they found: KPV was transported into cells through PepT1 and reduced activity in certain inflammatory signaling pathways. The researchers also observed reductions in several measures of intestinal inflammation in mice. Why it matters: This study connects a possible cellular transport mechanism with observations of anti-inflammatory activity in experimental models.
Limitations: The study used cultured cells and mice, not human clinical trial participants. It does not establish whether KPV produces comparable effects in people.
View publication →Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease
animalWhat researchers investigated: KPV's effects in two mouse models of intestinal inflammation, including whether its activity depended on the melanocortin-1 receptor. What they found: KPV-treated mice showed improvements in several measures of inflammation, including tissue-level inflammatory changes and recovery of body weight. The findings also suggested that some of KPV's activity may occur independently of MC1R signaling. Why it matters: The study examined KPV in more than one experimental model and explored a possible distinction between the peptide's activity and that of the larger α-MSH hormone.
Limitations: These were mouse experiments. The findings do not demonstrate effectiveness in human inflammatory bowel disease.
View publication →Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model
in-vitroWhat researchers investigated: Whether nanoparticles containing KPV could be delivered to the colon using a specialized hydrogel system. What they found: The delivery system reduced certain inflammatory measures in laboratory experiments and in mice with experimentally induced colitis. Why it matters: The study explored how the way a peptide is delivered can influence its experimental effects.
Limitations: The results relate to a specialized nanoparticle-and-hydrogel formulation. They cannot be assumed to apply to ordinary, unformulated KPV or to humans.
View publication →Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis
in-vitroWhat researchers investigated: A specialized nanoparticle delivery system designed to transport KPV to cells involved in intestinal inflammation. What they found: The researchers reported reduced inflammatory measures and improvements in experimental intestinal tissue outcomes using the targeted delivery system. Why it matters: The study extends earlier research into whether engineered delivery systems can change how KPV behaves in experimental models.
Limitations: The findings concern a particular experimental formulation and preclinical models. They do not establish that KPV is an effective treatment for ulcerative colitis in humans.
View publication →What We Still Don't Know
Does it work in humans? The preclinical findings do not establish whether KPV can produce meaningful clinical benefits in people. What is its human safety profile? The studies discussed here do not establish its short-term or long-term safety in humans. How important is the delivery method? Some experiments have used specialized nanoparticle formulations designed to deliver KPV to specific tissues. It is unclear how findings from those systems would translate to other formulations or delivery methods. Are its effects limited to particular tissues or inflammatory conditions? Much of the research discussed here focuses on intestinal inflammation. Its effects in other tissues and conditions require separate investigation. Which mechanisms matter most? Researchers have identified possible roles for PepT1 transport, NF-κB signaling, MAP kinase pathways, and mechanisms that may be partly independent of MC1R. Their relative importance in living humans remains unknown. What happens with repeated or prolonged exposure? The available preclinical findings do not establish the consequences of long-term human exposure.
Recent publications
Latest titles from PubMed, not reviewed by Aminodex. Not an endorsement. See all on PubMed ↗
Take the KPV research with you.
Get the Aminodex KPV Brief—a concise summary of the research, notable studies, evidence types, limitations, and references.
One-time email. We do not add you to any mailing list.
Sources & References
- Dalmasso G. et al. (2008). PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation. Gastroenterology, 134(1), 166–178.
- Kannengiesser K. et al. (2008). Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory Bowel Diseases, 14(3), 324–331.
- Laroui H. et al. (2010). Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model. Gastroenterology.
- Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis. (2017).
- The Tripeptide KdPT Protects from Intestinal Inflammation and Maintains Intestinal Barrier Function. (2011). Related-compound research, included for scientific context rather than as direct evidence for KPV.
Supplier Listings
Disclosure: The owner of Aminodex operates the supplier(s) marked below. These listings are promotion for businesses we own, not independent recommendations. Read our disclosures.